Bio Preventive Medicine Corp. announced on January 3, 2024 that its IVD product, DNlite-DKD uPTM-FetA ELISA Kit (aka DNlite-IVD103-DKD) has received marketing approval from Taiwan FDA. Before TFDA approval, DNlite-IVD103-DKD has gained it's official license in several markets, including EU, Malaysia, Thailand and Saudi Arabia. It is used as an aid in assessing the prognosis of kidney function in type 2 diabetes patients. The new and improved DNlite-IVD103 kit has a shorter operating time and streamlined transportation conditions compared to the previous generation.
Currently we are looking for global distribution partners. Please contact dnlite@bpmbiotech.com if interested.